-
公开(公告)号：CA2786335A1
公开(公告)日：2011-07-21
申请号：CA2786335
申请日：2011-01-13
Applicant: UCB PHARMA SA
Inventor： ELLIS MARK , HUMPHREYS DAVID PAUL
IPC: C12N15/70 , C07K14/245
Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.
-
公开(公告)号：CA2780242A1
公开(公告)日：2011-05-26
申请号：CA2780242
申请日：2010-11-17
Applicant: UCB PHARMA SA
Abstract: A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally VH1, a CH1 region and a further variable domain nominally VH2, a light chain comprising, in sequence from the N-terminal, a variable domain nominally VL1, a CL domain and a variable domain nominally VL2, wherein said heavy and light chains are aligned to provide a first binding site formed by a first variable domain pair of VH1 and VL1 and a second binding site formed by a second variable domain pair of VH2 and VL2, wherein there is a disulfide bond between a variable domain pair forming a binding site, and said fusion protein is conjugated to a PEG polymer.
-
公开(公告)号：CA2625144A1
公开(公告)日：2007-04-12
申请号：CA2625144
申请日：2006-09-29
Applicant: UCB PHARMA SA
Inventor： ELLIS MARK , HUMPHREYS DAVID PAUL
Abstract: The present invention provides a dicistronic message for producing an antibody molecule, in which the upstream cistron contains DNA coding for the light chain of the antibody and the downstream cistron contains DNA coding for the corresponding heavy chain, characterised in that the dicistronic message comprises a sequence selected from AEOSl (SEQ ID NO:1), AEOS2 (SEQ ID NO:2), AEOS3 (SEQ ID NO:3), AEOS4 (SEQ ID NO: 4), AEOS5 (SEQ ID NO:5), AEOS6 (SEQ ID NO:6), AEOS7 (SEQ ID NO:7), AEOS8 (SEQ ID NO:8), AEOS9 (SEQ ID NO:9), AEOSlO (SEQ ID NO:10) and AEOSl 1 (SEQ ID NO:11).
-
公开(公告)号：AU2004253746A1
公开(公告)日：2005-01-13
申请号：AU2004253746
申请日：2004-07-01
Applicant: UCB PHARMA SA
Inventor： HUMPHREYS DAVID PAUL , HEYWOOD SAM PHILIP , CARRINGTON BRUCE
Abstract: The present invention provides an antibody Fab or Fab' fragment to which at least one effector molecule is attached characterized in that the heavy chain in the fragment is not covalently bonded to the light chain and both the interchain cysteine of C L and the interchain cysteine of C H 1 have been replaced with another amino acid.
-
公开(公告)号：AU2004253738A1
公开(公告)日：2005-01-13
申请号：AU2004253738
申请日：2004-07-01
Applicant: UCB PHARMA SA
Inventor： HUMPHREYS DAVID PAUL , HEYWOOD SAM PHILIP
IPC: C07K16/00 , A61K39/395
Abstract: The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1 to which one or more effector molecules are attached.
-
Patent Agency Ranking
公开(公告)号：CA2855174C
公开(公告)日：2021-11-02
申请号：CA2855174
申请日：2012-11-09
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , BHATTA PALLAVI , HEYWOOD SAM PHILIP , HUMPHREYS DAVID PAUL
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, including a bispecific antibody fusion protein that binds OX40 and human scrum albumin, wherein the antigen bound by the first antigen binding site is human OX40, and the antigen bound by the second antigen binding site is human serum albumin. The invention also relates to therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：CA2856216C
公开(公告)日：2021-01-12
申请号：CA2856216
申请日：2012-11-09
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , BHATTA PALLAVI , HEYWOOD SAM PHILIP , HUMPHREYS DAVID PAUL
Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
-
公开(公告)号：AU2018201233B2
公开(公告)日：2019-06-06
申请号：AU2018201233
申请日：2018-02-21
Applicant: UCB PHARMA SA
Inventor： HUMPHREYS DAVID PAUL , PETERS SHIRLEY JANE
IPC: C07K16/00
Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterised in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation. 9995452_1 (GHMatters) P97849.AU.1
-
公开(公告)号：AU2013261915B2
公开(公告)日：2017-12-14
申请号：AU2013261915
申请日：2013-05-13
Applicant: UCB PHARMA SA
Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a.) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b.) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti Fc Rn antibodies and proteins made by the methods described herein.
-
公开(公告)号：EA023053B1
公开(公告)日：2016-04-29
申请号：EA201200725
申请日：2010-11-17
Applicant: UCB PHARMA SA
Abstract: Визобретенииописангибридныйбелокполивалентногоантитела, включающийтяжелуюцепь, содержащуюпоследовательнос N-концавариабельныйдоменноминально V1, область C1 идополнительныйвариабельныйдоменноминально V2, легкуюцепь, включающуюпоследовательнос N-концавариабельныйдоменноминально V1, домен CL ивариабельныйдоменноминально V2, причемуказанныетяжелуюи легкуюцепивыравниваютдляобеспеченияпервогосайтасвязывания, сформированногопервойвариабельнойдоменнойпарой V1 и V1, ивторогосайтасвязывания, сформированноговторойвариабельнойдоменнойпарой V2 и V2, причемимеетсядисульфиднаясвязьвнутривариабельнойдоменнойпары, формирующейсайтсвязывания, иуказанныйгибридныйбелокконъюгированс полимеромПЭГ.
-
-
-
-
-
-
-
-
-
Search Results
131
records
(took 0.023 seconds)
